Receptos Inc

Receptos — Technical Presentation (February 2015)

15 slides from Receptos's technical presentation, Feb 23, 2015

  1. Slide 1: Randomized Induction Trial of Ozanimod in Ulcerative Colitis: TOUCHSTONE Results

    Exhibit 99.1 A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator Ozanimod (RPC1063) in Moderate to Severe Ulcerative Colitis: Results of the TOUCHSTONE Study William Sandborn, MD 21 February 2015 Barcelona, Spain W. Sandborn¹, B. Feagan², D. Wolf³, G. D'H

  2. Slide 2: Conflict of Interest Statements

    Conflict of Interest Statements • W Sandborn- Financial support for research: Receptos, Jansen, Abbvie, Prometheus Laboratories, Pfizer, Amgen, Genentech, Takeda. Consultancy: Receptos, Jansen, Abbvie, UCB Pharma, Shire, Salix, Actavis, Prometheus Laboratories, Pfizer, Amgen, Genentech, Takeda • B F

  3. Slide 3: S1P1R Modulation Results in Sequestration of Select Lymphocyte Subsets

    S1P 1R Modulation Results in Sequestration of Select Lymphocyte Subsets • S1P1R signaling on CCR7+ lymphocytes (central memory T cells) facilitate their exit from lymph nodes along an S1P gradient • Ozanimod induces S1P 1R internalization so lymphocytes do not respond to S1P and are retained in the

  4. Slide 4: S1P1R Modulators

    S1P 1R Modulators • Fingolimod is the first S1P receptor modulator (S1P 1,3,4,5R ) and oral agent approved in 2010 for the treatment of Relapsing Multiple Sclerosis (RMS) • Well established efficacy and safety profile • Over 100,000 patients have been treated with Fingolimod • No increase in serious

  5. Slide 5: Patient Population: Key Inclusion/Exclusion Criteria

    Patient Population: Key Inclusion/Exclusion Criteria • Inclusion: • Adults with moderate to severe UC defined by a Mayo score of 6- 12 inclusive with endoscopic subscore 2 by central read • Receiving treatment with oral aminosalicylates and/or prednisone • Patients were allowed to receive MTX, 6-MP

  6. Slide 6: Study Design

    Study Design Induction Period Maintenance Period Primary Week 32 Endpoint: Maintenance 1 Week Dose 8 Weeks Induction 24 Weeks Endpoint Titration Treatment Treatment Placebo (N=65) Mayo Responders Randomization Ozanimod 0.5 mg (N=65) Ozanimod 1 mg (N=67) Disease Relapse Open-Label • Conducted at 57 s

  7. Slide 7: Study Endpoints and Methods

    Study Endpoints and Methods • Primary Efficacy Endpoint • Proportion of patients in clinical remission at Week 8, defined as a Mayo score 2 points with no subscore > 1 point • Key Secondary Efficacy Endpoints • Proportion of patients with clinical response at Week 8 • Change from Baseline in Mayo sc

  8. Slide 8: Patient Demographics and UC Disease History

    Patient Demographics and UC Disease History Placebo Ozanimod 0.5 mgOzanimod 1 mg (N=65) (N=65) (N=67) Demographics Male –n (%) 35 (53.8) 32 (49.2) 48 (71.6) Age (years)– mean (SD) 41.9 (12.3) 38.8 (12.1) 41.8 (11.0) UC Disease History YearssinceUCdiagnosis– mean(SD) 6.1 (5.5) 5.9 (5.4) 6.7 (6.8) May

  9. Slide 9: 1° Endpoint: Proportion of Patients in Remission at Week 8

    1° Endpoint: Proportion of Patients in Remission at Week 8 (Adjudicated Central Read) 20% p = 0.1422 p = 0.0482 16.4% 15% 13.8% 10% 6.2% 5% 0% Treatment Group Placebo (N=65) Ozanimod 0.5 mg (N=65) Ozanimod 1 mg (N=67)

  10. Slide 10: Comparison of 1° Endpoint: Original vs. Adjudicated Central Read

    Comparison of 1° Endpoint: Original Central Read vs. Adjudicated Central Read p = 0.0698 p = 0.0114 p = 0.1422 p = 0.0482 20% 17.9% 16.4% 15% 13.8% 13.8% 10% 6.2% 5% 4.6% 0% Original Central Read Adjudicated Central Read Placebo (N=65) Ozanimod 0.5 mg (N=65) Ozanimod 1 mg (N=67)

  11. Slide 11: 2° Endpoint: Proportion of Patients in Clinical Response at Week 8

    2° Endpoint: Proportion of Patients in Clinical Response at Week 8 (Adjudicated Central Read) 70% p = 0.0648 p = 0.0140 60% 58.2% 53.8% 50% 40% 36.9% 30% 20% 10% 0% Treatment Group Placebo (N=65) Ozanimod 0.5 mg (N=65) Ozanimod 1 mg (N=67)

  12. Slide 12: 2° Endpoint: Mucosal Improvement/Mucosal Healing

    2° Endpoint: Proportion of Patients With Mucosal Improvement/Mucosal Healing (Endoscopy score of 1 at Week 8, Adjudicated Central Read) p = 0.0348 p = 0.0023 40% 34.3% 30% 27.7% 20% 12.3% 10% 0% Treatment Group Placebo (N=65) Ozanimod 0.5 mg (N=65) Ozanimod 1 mg (N=67)

  13. Slide 13: Safety: Treatment Emergent Adverse Events

    Safety: Treatment Emergent Adverse Events Number of Subjects Placebo Ozanimod 0.5 mgOzanimod 1 mg (N=65) (N=65) (N=67) 1 TEAE 22 (33.8) 23 (35.4) 19 (28.4) Most Common TEAEs Placebo Ozanimod 0.5 mgOzanimod 1 mg Anemia / Decreased HgB 4 (6.2) 4 (4.6) 0 Worsening of UC 3 (4.6) 2 (3.1) 1 (1.5) Serious

  14. Slide 14: Safety: Holter Monitoring and Transaminase Elevations

    Safety: Holter Monitoring and Transaminase Elevations Placebo Ozanimod 0.25 mg 24-hr Holter Monitoring Findings (n=65) (n=132) Subjects withnd2Degree AVB 0 0 Subjects with Sinus Pause 0 0 Placebo Ozanimod 0.5 mg Ozanimod 1 mg ALT elevation > 3xULN (n=65) (n=65) (n=67) ALT elevation 0 2 (3.1) 1 (1.6)

  15. Slide 15: Conclusions

    Conclusions • Ozanimod 1 mg induced clinical remission at Week 8 (1 ° EP) • All 3 secondary endpoints were met for Ozanimod 1 mg at Week 8 • Proportion of patients with a clinical response • Change from baseline in Mayo score • Proportion of patients with mucosal improvement • A dose response relati

Receptos — Technical Presentation (February 2015) on 6ix